After nearly a decade of building one of the nation’s most robust biomedical innovation ecosystems, the Medical University of South Carolina (MUSC) has earned national recognition for its growing culture of innovation. The Cure Innovation Index evaluated universities across the country that conduct biomedical research, narrowing an initial pool of roughly 1,200 institutions down to 303 finalists based on research funding, output and 12 additional innovation-focused metrics. MUSC placed 44th overall, the highest-ranked university in the state, positioning it among the top 15% of ranked institutions nationwide.
“We knew that we were making good progress and have been extraordinarily proud of the outcomes and the progress that we've made over the last decade. It's always rewarding and gratifying to get external validation as well,” said MUSC’s chief innovation officer Jesse Goodwin, Ph.D. “It's one thing to say something about yourself. It's another thing to have someone else say it about you, too. And when it’s backed up by data, it’s even better.”
The Cure Innovation Index is the first national, data-driven platform designed to assess how effectively U.S. biomedical research institutions convert discovery into therapies, companies and measurable health outcomes. The inaugural 2026 index evaluated 303 leading institutions, spanning all 50 states, the District of Columbia and Puerto Rico, selected from more than 6,000 nationwide.
The index evaluates institutions across 25 indicators within three core domains: research capabilities, entrepreneurial readiness and market translation. Together, these dimensions capture the structural, cultural and operational factors that enable institutions to move breakthroughs beyond the lab and into real-world application.
MUSC demonstrated strong performance across all three domains, earning “Excellent” ratings in four key areas: cutting-edge science, facilities and equipment, faculty engagement and industry connections. These distinctions highlight the University’s depth in biomedical research, the strength of its advanced infrastructure and core facilities and a highly engaged faculty driving discovery and innovation.
“Innovation follows discovery, and that discovery component is the research component. And so, the output from the innovation group is a direct follow-through of the incredible research that we're also doing. It's a direct line between those two,” said MUSC’s vice president of Research Timothy Stemmler, Ph.D. “This shows the impact that the innovation group is really having on the MUSC landscape. These people are working really hard. They're doing incredible things. They are so well organized; they're targeted, and they're strategic.”
This shows the impact that the innovation group is really having on the MUSC landscape. These people are working really hard. They're doing incredible things. They are so well organized; they're targeted, and they're strategic.
That strategic planning led to an innovation ecosystem that allows anyone in the enterprise to submit an idea for consideration and see it developed all the way through implementation. MUSC offers a gateway to collect these ideas as well as support from the Zucker Institute for Innovation Commercialization to develop and coach potential entrepreneurs.
To support these innovators further, MUSC recently launched its first venture fund, 1824 Health Ventures, to move ideas across the finish line. The fund has committed $20 million to support strictly internal startups over the next five years.
While its internal innovation system has been growing, MUSC has also cultivated a robust portfolio of strategic partnerships, including Siemens Healthineers, Medtronic and Helix, underscoring its growing influence as a national hub for health innovation. From advancing new therapies and startup companies to expanding precision medicine and population health initiatives, the University continues to translate research into tangible improvements in patient care and health outcomes. “I was quite pleased to see these rankings but not surprised,” said Wendy Minor, executive director of the Office of Strategic Partnerships and External Affairs. “Nearly a decade ago, MUSC made a deliberate decision to pursue strategic partnerships that could help us to expand our capabilities, accelerate discovery and serve the people of South Carolina more robustly. The success we’re seeing today is a reflection of that vision. To see firsthand how these partnerships have blossomed from just a little spark shows how nimble and forward-leaning MUSC is.”
As MUSC continues to expand its research enterprise, strategic partnerships and commercialization efforts, leaders say the ranking reflects more than national recognition; it signals growing momentum in the University’s mission to translate discovery into better care, stronger partnerships and improved health outcomes for patients across South Carolina and beyond.
“I'm proud of the collective work that everyone's been doing for a decade to have this recognized,” said Goodwin.
I'm proud of the collective work that everyone's been doing for a decade to have this recognized.
